{
    "ticker": "RFL",
    "name": "Rafael Holdings, Inc.",
    "description": "Rafael Holdings, Inc. is a biotechnology company focused on the development of innovative cancer therapies. The company is committed to advancing cutting-edge treatments that target specific cancer cell pathways, with a vision to improve patient outcomes and quality of life. Founded in 2016 and headquartered in Newark, New Jersey, Rafael Holdings operates through its subsidiary, Rafael Pharmaceuticals, which is engaged in the development of a proprietary cancer treatment platform. The company\u2019s lead product candidate, devimistat (also known as CPI-613), is in clinical trials for various types of cancer, including pancreatic cancer and hematological malignancies. Rafael Holdings is dedicated to leveraging its scientific expertise and collaboration with leading research institutions to explore new therapeutic avenues. With a focus on innovation and patient-centric solutions, the company aims to be at the forefront of the fight against cancer, pursuing a mission to transform cancer care through groundbreaking therapies and partnerships.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Newark, New Jersey, USA",
    "founded": "2016",
    "website": "https://www.rafaelholdings.com",
    "ceo": "Bill Roth",
    "social_media": {
        "twitter": "https://twitter.com/RafaelHoldings",
        "linkedin": "https://www.linkedin.com/company/rafael-holdings-inc"
    },
    "investor_relations": "https://www.rafaelholdings.com/investor-relations",
    "key_executives": [
        {
            "name": "Bill Roth",
            "position": "CEO"
        },
        {
            "name": "Michael W. Houghton",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "Devimistat (CPI-613)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Rafael Holdings, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Rafael Holdings, Inc., a biotechnology company dedicated to developing innovative cancer therapies. Learn about their lead product and commitment to improving patient outcomes.",
        "keywords": [
            "Rafael Holdings",
            "Cancer Therapies",
            "Biotechnology",
            "Pharmaceuticals",
            "Devimistat",
            "CPI-613"
        ]
    },
    "faq": [
        {
            "question": "What is Rafael Holdings known for?",
            "answer": "Rafael Holdings is known for developing innovative cancer therapies, particularly its lead product candidate, devimistat."
        },
        {
            "question": "Who is the CEO of Rafael Holdings?",
            "answer": "Bill Roth is the CEO of Rafael Holdings, Inc."
        },
        {
            "question": "Where is Rafael Holdings headquartered?",
            "answer": "Rafael Holdings is headquartered in Newark, New Jersey, USA."
        },
        {
            "question": "What are Rafael Holdings' main products?",
            "answer": "The main product of Rafael Holdings is devimistat (CPI-613), which is in clinical trials for various cancers."
        },
        {
            "question": "When was Rafael Holdings founded?",
            "answer": "Rafael Holdings was founded in 2016."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "MRNA",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ABBV",
        "JNJ"
    ]
}